Tourmaline Bio (TRML) has released an update.
Tourmaline Bio, Inc. entered into an underwriting agreement with several underwriters for the sale of 4,615,384 shares at $32.50 each, with an additional option for 692,307 shares, which the underwriters exercised in full. The offering, expected to close on January 29, 2024, should yield approximately $172.5 million in gross proceeds, or about $161.4 million net after expenses. The proceeds will fund clinical development and general corporate purposes. The offering includes customary terms and an opinion on the shares’ validity from Cooley LLP.
For further insights into TRML stock, check out TipRanks’ Stock Analysis page.
